On Tuesday, August 16, there will be another meeting of the Transparency Council.
AOTMiT: Transparency Council incl. about diagnostic tests
Published Aug. 8, 2022 08:34
Źródło: AOTMiT
The agenda includes:
Preparation of a position on the assessment of the legitimacy of introducing into the list of guaranteed services in the field of primary health care, financed from the entrusted budget, selected tests: diagnostic, ultrasound, invasive, electrophysiological and functional, as well as specialist advice and consultations.
Preparation of opinions on recommended medical technologies, activities carried out within the framework of health policy programs and the conditions for their implementation in the field of glaucoma prevention.
Preparation of drug assessment positions:
• Ontozry (cenobamate) in the indication: adjunctive treatment of focal seizures undergoing or non-generalizing in adult epilepsy patients with uncontrollable or intolerant treatment after at least one add-on therapy attempt,
• Empliciti (elotuzumabum) as part of the drug program: B.54. "Treatment of patients with multiple myeloma (ICD-10: C90.0).
Preparation of an opinion on the coverage of drugs containing active substances with reimbursement:
• azathioprinum in the indications: sarcoidosis; interstitial pneumonia - other than those specified in the SmPC - except for idiopathic pulmonary fibrosis; granulomatous lung diseases - other than those specified in the SPC,
• cyclophosphamidum in the indications: sarcoidosis; interstitial pneumonia - other than those specified in the SPC - except for idiopathic pulmonary fibrosis
• methotrexatum in the indications: sarcoidosis; Granulomatous lung diseases - in cases other than those specified in the SmPC.
Source: AOTMiT
